December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

87.47 +2.91 (+3.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 900,325
Open 86.58
Bid (Size) 75.00 (100)
Ask (Size) 91.42 (200)
Prev. Close 84.56
Today's Range 84.22 - 87.84
52wk Range 12.84 - 97.78
Shares Outstanding 14,410,143
Dividend Yield 22.13%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean ↗
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? ↗
This Menlo Park biotech specializing in antibody therapies saw a notable insider sale following a year of rapid gains in its share price. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+209.4%
+209.4%
1 Month
+27.0%
+27.0%
3 Month
+30.4%
+30.4%
6 Month
+179.1%
+179.1%
1 Year
+495.0%
+495.0%

More News

Read More
News headline image
An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Tiny Biotech Just Beat AbbVie's $17 Billion Drug. Should Investors Be Worried? ↗
Via The Motley Fool
News headline image
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
From Oruka Therapeutics, Inc.
Via GlobeNewswire
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oruka Therapeutics Announces New Board Member and Board Transition
From Oruka Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Oruka Therapeutics, Inc. - Common Stock publicly traded?
Yes, Oruka Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Oruka Therapeutics, Inc. - Common Stock trade on?
Oruka Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Oruka Therapeutics, Inc. - Common Stock?
The ticker symbol for Oruka Therapeutics, Inc. - Common Stock is ORKA on the Nasdaq Stock Market
What is the current price of Oruka Therapeutics, Inc. - Common Stock?
The current price of Oruka Therapeutics, Inc. - Common Stock is 87.47
When was Oruka Therapeutics, Inc. - Common Stock last traded?
The last trade of Oruka Therapeutics, Inc. - Common Stock was at 07/14/26 04:00 PM ET
What is the market capitalization of Oruka Therapeutics, Inc. - Common Stock?
The market capitalization of Oruka Therapeutics, Inc. - Common Stock is 1.26B
How many shares of Oruka Therapeutics, Inc. - Common Stock are outstanding?
Oruka Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.